# Michigan State University

Organization · id `cardio:org-michigan-state-university` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ROR record 05hs6h993](<https://ror.org/05hs6h993>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class other. Matched to ROR record 05hs6h993 by an exact name.

## The registry's words

- Sponsor name: Michigan State University
- Sponsor class: OTHER
- ROR name: Michigan State University

## Connected pages

- Sponsors: Risk Reduction for Alzheimer's Disease (`cardio:ct-nct02913664`)
- Sponsors: Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study) (`cardio:ct-nct05331144`)
- Sponsors: Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients (`cardio:ct-nct07749014`)

## Provenance

Content hash: 24b3308326061f0d86b224b5b96650d82db29b03800f43b189299703b55a0e85
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
